AMENDMENT

In the Specification:

Please delete the paragraph at lines 3-14 on page 1. Applicants hereby disclaim priority in this application to any previous filing.

In the Claims:

Please amend the claims as follows:

Please replace the presently pending claims with the following claims:

Please cancel claims 2-6.

7. (Amended) A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the immunogenic peptide comprises a sequence selected from the group consisting of:

YLSGANLNV (SEQ. ID. NO: 3),
SMPPPGTRV (SEQ. ID. NO: 4),
SLPPPGTRV (SEQ. ID. NO: 5),
ALNKMFBQV (SEQ. ID. NO: 8),
KLBPVQLWV (SEQ. ID. NO: 9),
YVCGIQNSV (SEQ. ID. NO: 31),
ATVGIMIGV (SEQ. ID. NO: 33),
FMYSDFHFI (SEQ. ID. NO: 182),
NMLSTVLGV (SEQ. ID. NO: 183),
SLENFRAYV (SEQ. ID. NO: 184),
VLLGVVFGV (SEQ. ID. NO: 188), and
YLIMVKBWMV (SEQ. ID. NO: 191).

8. (Amended) The composition of claim 7, wherein the sequence is from a cancer-associated antigen and is selected from the group consisting of SEQ. ID. NOs: 3-5, 8, 9, 31, 33, 188, and 191.

9. (Amended) The composition of claim 8, wherein the cancer-associated antigen is p53 and the sequence is selected from the group consisting of SEQ. ID. NOs: 4, 5, 8, and 9.

Please cancel claim 10.

11. (Amended) The composition of claim 9, wherein the sequence is SEQ ID NO: 4.

12. (Amended) The composition of claim 8, wherein the cancer-associated antigen is carcinoembryonic antigen (CEA) and the peptide is selected from the group consisting of SEQ. ID. NOs: 31 and 33.

Please cancel claim 13.

14. (Amended) The composition of claim 8, wherein the cancer-associated antigen is Her2/neu and the peptide is SEQ. ID. NO: 188 or 191.

Please cancel claim 15.

16. The composition of claim 7, further comprising a pharmaceutically acceptable carrier.

17. (Amended) The composition of claim 7, wherein the immunogenic peptide of less than about 15 amino acids in length that comprises the HLA-A2.1 binding motif is linked to a T helper peptide.

18. The composition of claim 7, wherein the peptide is linked to a lipid.

19. The composition of claim 7, wherein the peptide is linked to a different peptide that induces a cytotoxic T lymphocyte response.

20. The composition of claim 7, further comprising a liposome.

21. The composition of claim 7, wherein the peptide is completed with an HLA-A2.1 molecule that is present on an antigen-presenting cell

22. The composition of claim 21, wherein the antigen-presenting cell is a dendritic cell.

Please add the following claims:

23. (New) The composition of claim 7, wherein said antigen is a flu antigen selected from the group consisting of SEQ. ID. NOs: 182, 183 or 184.

24. (New) A method to produce a cellular immune response in a subject which comprises contacting cytotoxic T cells from said subject with the composition of claim 7.